The therapeutic relevance of a
Thymoma
breast cancer gene 2 (BRCA2)
case report
olaparib
poly (ADP-ribose) polymerase inhibitor (PARP inhibitor)
Journal
Mediastinum (Hong Kong, China)
ISSN: 2522-6711
Titre abrégé: Mediastinum
Pays: China
ID NLM: 101731833
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
02
2022
accepted:
21
07
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Thymomas are characterized by a low tumor mutation burden and a paucity of actionable mutations. Clinical behavior can vary from relatively indolent to very aggressive and impact survival. Platinum-based chemotherapy is the primary treatment modality for inoperable disease and is palliative in intent. Patients with advanced thymoma frequently experience disease recurrence after frontline therapy. Treatment options for relapsed thymoma are relatively limited. A case of recurrent thymoma harboring a breast cancer gene 2 ( A 63-year-old female presented with Tumor Node Metastasis (TNM) stage I, World Health Organization (WHO) subtype B1 thymoma at diagnosis and underwent surgical resection. First recurrence occurred in the left costophrenic recess and was treated with preoperative external beam radiotherapy (EBRT), surgical excision, and post-operative chemotherapy. Histology was consistent with WHO subtype B2 thymoma and genomic analysis of the resected tumor detected a A potential role of poly (ADP-ribose) polymerase (PARP) inhibitors versus cytotoxic chemotherapy for treatment of
Sections du résumé
Background
UNASSIGNED
Thymomas are characterized by a low tumor mutation burden and a paucity of actionable mutations. Clinical behavior can vary from relatively indolent to very aggressive and impact survival. Platinum-based chemotherapy is the primary treatment modality for inoperable disease and is palliative in intent. Patients with advanced thymoma frequently experience disease recurrence after frontline therapy. Treatment options for relapsed thymoma are relatively limited. A case of recurrent thymoma harboring a breast cancer gene 2 (
Case Description
UNASSIGNED
A 63-year-old female presented with Tumor Node Metastasis (TNM) stage I, World Health Organization (WHO) subtype B1 thymoma at diagnosis and underwent surgical resection. First recurrence occurred in the left costophrenic recess and was treated with preoperative external beam radiotherapy (EBRT), surgical excision, and post-operative chemotherapy. Histology was consistent with WHO subtype B2 thymoma and genomic analysis of the resected tumor detected a
Conclusions
UNASSIGNED
A potential role of poly (ADP-ribose) polymerase (PARP) inhibitors versus cytotoxic chemotherapy for treatment of
Identifiants
pubmed: 36582974
doi: 10.21037/med-22-9
pii: med-06-40
pmc: PMC9792822
doi:
Types de publication
Case Reports
Langues
eng
Pagination
40Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
2022 Mediastinum. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-22-9/coif). EMM received an honorarium from Boehringer Ingelheim. A Rimner received grants to his institution from Boehringer Ingelheim, Pfizer, AstraZeneca, Varian Medical Systems, and Merck; and personal grants from Boehringer Ingelheim, AstraZeneca, Merck, Cybrexa, MoreHealth, ResearchToPractice, and Philips/Elekta. ACR received yearly royalties from Up-to-Date. DB received an honorarium from AstraZeneca. MS serves as an unpaid editorial board member of Mediastinum from June 2021 to May 2023. ACR serves as an unpaid Associate Editor of Mediastinum from July 2021 to June 2023. MM serves as an unpaid Associate Editor-in-Chief of Mediastinum. NT serves as an unpaid editorial board member of Mediastinum from June 2021 to May 2023. CF serves as an unpaid editorial board member of Mediastinum from July 2021 to June 2023. The other authors have no conflicts of interest to declare.
Références
J Thorac Oncol. 2018 Dec;13(12):1940-1948
pubmed: 30121390
Cancers (Basel). 2020 Feb 08;12(2):
pubmed: 32046278
Nat Rev Drug Discov. 2020 Oct;19(10):711-736
pubmed: 32884152
Sci Rep. 2014 Dec 08;4:7336
pubmed: 25482724
Lancet Haematol. 2021 Feb;8(2):e122-e134
pubmed: 33347814
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
Oncologist. 2020 Apr;25(4):301-305
pubmed: 32297440
J Clin Pharm Ther. 2021 Jun;46(3):571-584
pubmed: 33421183
J Pathol. 2013 Aug;230(4):347-9
pubmed: 23620175
Cancer Cell. 2018 Feb 12;33(2):244-258.e10
pubmed: 29438696
Front Oncol. 2018 Feb 05;8:16
pubmed: 29459887
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245040